Dr John Melki – CEO and Director – Genetic Signatures (ASX:GSS) is transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays.
Copyright 2023 – Finance News Network
Source: Finance News Network
16 Aug 2023 - Tom Spurling - Executive Director - Nova Eye Medical (ASX:EYE) is introducing a comprehensive portfolio of novel glaucoma treatment options which span the entire disease process – enabling physicians to intervene earlier, and more often, in the treatment of glaucoma.
Read More05 Apr 2023 - North Stawell Minerals Limited (ASX:NSM) CEO Russell Krause provides an update, discussing the company's progress to date, the most prospective targets, and milestones ahead.
Read More23 Sep 2019 - SUDA Pharmaceuticals Limited (ASX:SUD) Managing Director & CEO, Stephen Carter discusses the company's portfolio and the benefits of reformulating and delivering medication through the oral mucosa.
Read More05 Feb 2025 - CEO Andrew Terry discusses long-range wi-fi, semiconductor challenges, and the future of IoT connectivity.
Read More25 March 2024 - Altech Batteries Limited (ASX:ATC) Managing Director Iggy Tan provides an update on the company, discussing funding pathways and the results of the DFS.
Read More09 Apr 2025 - Martin Stein discusses the supply chain, environmental, and ethical challenges of lithium-ion batteries and the benefits of Altech’s alternative
Read More03 Nov 2022 - Antisense Therapeutics Limited (ASX:ANP) Chair, Dr Charmaine Gittleson, and new Chief Commercial Officer, Dr Anthony Filippis, discuss Antisense's progress, attracting new talent to the company, and what drew Dr Filippis to the role.
Read More01 Sep 2021 - Novatti Group Limited (ASX:NOV) CEO Peter Cook, discusses highlights from FY21, including growth in partners and transactions as the company's technology finds greater adoption and new markets.
Read More11 Dec 2024 - INOVIQ's recent validation study of its EXO-OC test revealed it can detect stage one ovarian cancer with 96% specificity and more than 90% sensitivity, a promising advance for early detection.
Read More15 Nov 2022 - OncoSil Medical Limited (ASX:OSL) Non-Executive Director Brian Leedman discusses joining the board of OncoSil and receiving CE mark approval for the company's therapy.
Read More
